Melanoma Vaccine
Allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 has been developed
Published in Cancer Weekly, March 7th, 2006
According to scientists in the United States, "A xenogeneic melanoma-antigen-enhanced allogeneic tumor cell vaccine (ATCV) is an appealing strategy for anti-cancer immunotherapy due to its relative ease of production, and the theoretical possibility that presentation of a multiplex of antigens along with a xenogeneic antigen would result in cross-reaction between the xenogeneic homologs and self-molecules, breaking tolerance and ultimately resulting in a clinically relevant immune response."
"In this study, we evaluated the efficacy of such a strategy...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-03-07)
More Articles from Cancer Weekly
- Breast Cancer
Fuzzy c-means clustering-based method used to segment breast lesions from MRI - Cancer Diagnostics
CD10 expression used to differentiate trichoepithelioma from basal cell cancer - Lung Cancer
A GSTP1 polymorphism may be linked to survival in advanced non-small cell lung carcinoma - Lymphoma
Phosphatidylinositol-3 kinase/Akt inhibition promoted apoptosis in Hodgkin lymphoma - Prostate Cancer
Expandable endorectal coils used to improve alignment of prostate MR images - Adrenocortical Cancer
Therapeutic strategies for treating adrenocortical carcinoma discussed - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
